Daxor Corp (DXR) Stock Price, Quote & News

Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Website: www.daxor.com

Address:

109 Meco Lane, Oak Ridge, United States

Finanz Sep. 3 at 5:59 PM

$DXR The trading volume is so low.

0 · Reply

TechGrowthCapital Aug. 23 at 11:29 AM

$DXR Daxor Corporation is facing medical device adoption challenges and limited market

0 · Reply

Finanz Aug. 17 at 5:51 PM

$DXR Amazing chart. One day of huge volume and back down to tiny volume. Liquidity is the problem.

0 · Reply

alphawolftrading Aug. 13 at 4:32 PM

$DXR has been around a long time. The company has a new device that will change outcomes for many healthcars issues. The company needs insurers, clinics, Hospitals, clinicians, and patients to understand why this product is such a huge game-changer that will save lives. If your clinic or hospital does not have this tool, you should ask them why. By making others aware, that question may lead to saving someone's life. Supporting Daxor in their mission to improve healthcare for everyone. That is something meaningful that you can feel good about. That is the kind of positive impact we want to be part of at Alpha Wolf Impact Club. https://youtu.be/CwwO0-KvoFQ?si=JzuSK8jlRUFfgbN5

0 · Reply

alphawolftrading Aug. 13 at 6:23 AM

$DXR with their recent 510k Clearance on this portable blood analyzer that is 3 times faster than its predecessor, while needing less of a blood draw. The challenge now is to get clinicians, patients, hospitals, clinics, and insurers. To recognize the impact this new unit is going to have. Better health care outcomes and a better quality of life for patients. Every Hospital and clinic should have these. Take the guesswork out of healthcare and install the right tools to get the job done precisely and accurately. Daxor has one of the answers to make things better for all of humanity. https://youtu.be/CwwO0-KvoFQ?si=O-VyeOxGBdXG6FgT

0 · Reply

MasterofThePennies Aug. 12 at 6:57 PM

$DXR not actively trading much at the moment, market seems very weak for small caps in my opinion. DXR is my only swing stock at the moment. Feel this will be a very good play if you have patience.

0 · Reply

sirjohann Aug. 11 at 8:38 AM

$DXR wtf happen to this company

0 · Reply

PaulLaurent Aug. 7 at 7:06 PM

📢📊 Unusual Volume Stocks 📊📢 $DXR $STEC $WORX $BKYI $MYSZ

0 · Reply

FreeBeerTomorrow Aug. 7 at 7:01 PM

$DXR Trend has been, the big run is a day or 2 after the news drop. Just saying

1 · Reply

Toffeepanda Aug. 7 at 6:29 PM

$DXR "Amazing news—it's truly fantastic!"

0 · Reply

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Sep 23, 2025, 8:00 AM EDT - 13 days ago

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Sep 4, 2025, 8:00 AM EDT - 4 weeks ago

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Aug 7, 2025, 7:55 AM EDT - 2 months ago

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Jul 22, 2025, 8:00 AM EDT - 2 months ago

Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions

May 14, 2025, 8:00 AM EDT - 5 months ago

Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

May 13, 2025, 8:00 AM EDT - 5 months ago

Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

May 7, 2025, 8:00 AM EDT - 5 months ago

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

May 6, 2025, 8:00 AM EDT - 5 months ago

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance

Apr 22, 2025, 8:00 AM EDT - 5 months ago

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

Apr 15, 2025, 8:00 AM EDT - 6 months ago

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Apr 2, 2025, 8:00 AM EDT - 6 months ago

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo

Mar 28, 2025, 8:00 AM EDT - 6 months ago

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Mar 6, 2025, 9:00 PM EST - 7 months ago

Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:55 PM EST - 7 months ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Mar 4, 2025, 3:53 PM EST - 7 months ago

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Mar 4, 2025, 9:00 AM EST - 7 months ago

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Mar 4, 2025, 8:00 AM EST - 7 months ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Feb 28, 2025, 8:00 AM EST - 7 months ago

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Feb 27, 2025, 8:00 AM EST - 7 months ago

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Feb 19, 2025, 8:00 AM EST - 8 months ago

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

Feb 18, 2025, 10:50 AM EST - 8 months ago

TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

ARDT

Feb 18, 2025, 8:00 AM EST - 8 months ago

Daxor to Exhibit at World's Largest Critical Care Conference

Feb 14, 2025, 8:00 AM EST - 8 months ago

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

Feb 13, 2025, 8:00 AM EST - 8 months ago

New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Dec 18, 2024, 8:00 AM EST - 10 months ago

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Oct 9, 2024, 8:00 AM EDT - 1 year ago

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 5:00 PM EDT - 1 year ago

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Sep 4, 2024, 8:30 AM EDT - 1 year ago

Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

Sep 3, 2024, 12:15 PM EDT - 1 year ago

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

Mar 25, 2024, 8:05 PM EDT - 1 year ago

Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

Mar 18, 2024, 2:18 PM EDT - 1 year ago

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

Mar 8, 2024, 8:00 AM EST - 1 year ago

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients

Feb 26, 2024, 8:00 AM EST - 1 year ago

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions

Jan 2, 2024, 8:30 AM EST - 1 year ago

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Nov 13, 2023, 8:00 AM EST - 2 years ago

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients

Finanz Sep. 3 at 5:59 PM

$DXR The trading volume is so low.

0 · Reply

TechGrowthCapital Aug. 23 at 11:29 AM

$DXR Daxor Corporation is facing medical device adoption challenges and limited market

0 · Reply

Finanz Aug. 17 at 5:51 PM

$DXR Amazing chart. One day of huge volume and back down to tiny volume. Liquidity is the problem.

0 · Reply

alphawolftrading Aug. 13 at 4:32 PM

0 · Reply

alphawolftrading Aug. 13 at 6:23 AM

0 · Reply

MasterofThePennies Aug. 12 at 6:57 PM

$DXR not actively trading much at the moment, market seems very weak for small caps in my opinion. DXR is my only swing stock at the moment. Feel this will be a very good play if you have patience.

0 · Reply

sirjohann Aug. 11 at 8:38 AM

$DXR wtf happen to this company

0 · Reply

PaulLaurent Aug. 7 at 7:06 PM

📢📊 Unusual Volume Stocks 📊📢 $DXR $STEC $WORX $BKYI $MYSZ

0 · Reply

FreeBeerTomorrow Aug. 7 at 7:01 PM

$DXR Trend has been, the big run is a day or 2 after the news drop. Just saying

1 · Reply

Toffeepanda Aug. 7 at 6:29 PM

$DXR "Amazing news—it's truly fantastic!"

0 · Reply

WhaleHunt Aug. 7 at 5:59 PM

$DXR act like no new .. weird

0 · Reply

jreddyN Aug. 7 at 5:09 PM

$DXR After great news, why not fly? I expected this will be 20 to 25+

1 · Reply

cjstocksup Aug. 7 at 4:01 PM

$DXR I read through the 7/24 filings and there may be a little dilution happening. Otherwise we would be over $20.00 IMO. Go through and see what you find on the proposed offering. It looked small but it is affecting it.

1 · Reply

flashdash Aug. 7 at 3:37 PM

$DXR ----$HEARTFLOW (HTFL) is about to go public with a VERY HIGH market cap imo.......$DXR should be trading at a higher valuation than presently imo......

0 · Reply

DEEZNUTTS2112 Aug. 7 at 2:26 PM

$DXR feeling squeezy

0 · Reply

cjstocksup Aug. 7 at 2:10 PM

$DXR The news is forever game changing, but we will need to get over $15.00 to get the move to $20.00 to $30.000 later today. That is what should happen on this kind of news and low float, but we must first break and hold $15.00. Let's see.

0 · Reply

_www_larval_com_ Aug. 7 at 2:02 PM

$DXR just soared 9% higher to 8% (~1Mv) a moment ago, follow for more volatility.

0 · Reply

cjstocksup Aug. 7 at 2:01 PM

$DXR This stock has been very tightly held all year. It has had a nice steady climb. Here where it is up almost 100% on the year there could be some profit taking. Not alot of institutional ownership so retail traders can slow things up. The good news is today's news is game changing news for the company. If a group buys up wat is available of the low 2.1 million share float, we should see $20.00 to $30.00 later. I would bet on institutions getting involved now also. JMO

0 · Reply

Market Cap	67.23M
Revenue (ttm)	1.45M
Net Income (ttm)	-7.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-495.86%
Debt to Equity Ratio	0.00

Volume	4,500
Avg Vol	35,514
Day's Range	N/A - N/A
Shares Out	4.84M
Stochastic %K	92%
Beta	-0.06
Analysts	Strong Sell
Price Target	$23.50